Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 1

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
(Unaudited)

Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share data)2025202420252024Operating expensesResearch and development$(49,762)$(23,662)$(86,221)$(36,676)General and administrative(10,936)(6,916)(21,962)(13,723)Total operating expenses(60,698)(30,578)(108,183)(50,399)Operating loss(60,698)(30,578)(108,183)(50,399)Interest expense(2,037)—(2,056)—Other income, net6,7795,89813,87611,814Loss before income tax(55,956)(24,680)(96,363)(38,585)Income tax expense(95)(79)(248)(149)Net loss$(56,051)$(24,759)$(96,611)$(38,734)Of which: net loss attributable to controlling interests shareholders(55,220)(24,267)(95,165)(37,940)Of which: net loss attributable to noncontrolling interests shareholders(831)(492)(1,446)(794)Net unrealized gain (loss) on marketable securities and short-term investments(1,908)652(4,664)834Actuarial gain (loss) on employee benefit plans13(76)1085Other comprehensive income (loss)(1,895)576(4,556)839Comprehensive loss$(57,946)$(24,183)$(101,167)$(37,895)Comprehensive loss attributable to controlling interests shareholders(57,087)(23,703)(99,651)(37,119)Comprehensive loss attributable to noncontrolling interests(859)(480)(1,516)(776)Weighted-average number of Class A Ordinary Shares, basic and diluted63,282,72862,874,63763,258,39362,755,925Basic and diluted net loss per share attributable to controlling interests shareholders$(0.87)$(0.39)$(1.50)$(0.60) 

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.    

3

MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY(Unaudited)

Class A Ordinary SharesClass C Ordinary SharesAdditional Paid-In Capital